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ABSTRACT 
Objective: The aim of the present work was to design and synthesize 2, 3-aryl substituted 1, 3-benzoxazin-4-one derivatives and evaluate them for 
in-vitro antiproliferative activity against human breast adeno-carcinoma cells.  
Methods: The compounds were synthesized and screened for in-vitro antiproliferative activity against MCF-7 cell lines using 96 well plate method.  
Maharishi Markandeshwar College of Pharmacy, Mullana, Ambala, 
Haryana, India. 
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Results: 3 out of 9 synthesized compounds showed good in-vitro inhibition of MCF-7 cell lines. Compound 2 showed least IC50 (highest active) i.e. 
0.89 µg followed by compound 4 (IC50= 1.02 µg) and compound 3 (IC50
Keywords: 1, 3-benzoxazin-4-one, Antiproliferative activity, MCF-7 cell lines, Molecular docking. 
= 1.19 µg). 4 compounds showed more than 90 % inhibition at 100 µg after 
48 h incubation.  
Conclusion: This class of compounds showed some initial promising activity, which can be further expanded by synthesizing and testing more 
analogs of this kind against MCF-7 cell lines which may give good leads to proceed.  
 
INTRODUCTION 
4H-1, 3-benzoxazin-4-one derivatives have become an important 
class of compounds due to their interesting biological properties. 
Benzoxazinone derivatives have been used as antiphlogistics, 
antifungal and antibacterial agent [1]. Various benzoxazinones such 
as 1, 3-benzoxazinones, 1, 4 and 2, 4-benzoxazinones have been 
synthesized and tested for several biological activities.  
These include anti-inflammatory, anticancer and anticoagulant 
activities. Certain benzoxazinones have shown good potential as 5-
HT (1A) receptor antagonists with promising potent 5-HT reuptake 
inhibitor activity [2]. Apart from this, many benzoxazinones have 
shown antiviral activity. A few of these were active against herpes 
simplex virus (HSV) too [3].  
Some others were found to be active against human cytomegalo 
virus (CMV) by inhibiting CMV protease [4]. Certain benzoxazinones 
have been accredited with inhibitory activity against HIV reverse 
transcriptase enzyme which has given some prominence to this class 
of compounds [5].  
Cancer is a significant worldwide health problem generally due to 
the lack of widespread and comprehensive early detection methods 
[6]. Indeed, the struggle to combat cancer is one of the greatest 
challenges of mankind. Over-expression of EGFR (a receptor 
tyrosine kinase) has been associated with aggressive disease and 
poor patient prognosis in a range of human tumor types (e.g. breast, 
lung, ovarian, prostate, and squamous carcinoma of head and neck) 
[7]. Disruption of signal transduction of EGFR has been shown to 
have an antiproliferative and therapeutic effect [8]
In the present work, 9 derivatives of 2, 3-substituted benzoxazin-4-
one were synthesized and in-vitro antiproliferative assay was 
performed for all compounds using MTT (3-(4,5-
. Recently, some 
substituted benzoxazinones (bioisosters of marketed drugs like 
Gefitinib and Lapatinib) have shown epidermal growth factor 
receptor (EGFR) inhibitory effect [9], which is involved in cell 
growth, survival and differentiation of cancer.  
dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) method on MCF-7 cell lines 
(EGFR positive cell lines). Instead of substitutions on 4 and 6 
positions, we attached ring substitutions at 2 and 3 positions of 
benzoxazine ring to study their effect on in-vitro activity.  
MATERIALS AND METHODS 
All Solvents, reagents and chemicals used in this work were 
purchased from Aldrich, Spectrochem Pvt. Ltd., S. D. Fine Chem. Pvt. 
Ltd. and used as such. The reactions were monitored by thin layer 
chromatography (TLC) carried out on 0.25 mm E. Merck silica gel 
plates (silica gel 60 F254
Solvent free microwave irradiation method was followed to prepare 
N-phenyl salicylamide [11]. Equimolar quantities of phenyl 
salicylate and aniline were mixed and subjected to microwave 
irradiation for 5 min. The reaction was stopped when the 
temperature reached 180 ºC. The reaction mixture was cooled to 
room temperature and the mixture was treated with 
dichloromethane. The insoluble impurities were filtered off and the 
solvent was evaporated to get N-phenyl salicylamide. The product 
was then washed with 2 M HCl to remove access of aniline and then 
purified by column chromatography using hexane-ethyl acetate 
(3:1) as a solvent system.  
). Purification of synthesized compounds was 
performed by column chromatographic technique using silica gel 
100-200 mesh (E. Merck). Melting points were determined by using 
laboratory melting point apparatus (Toshniwal Pvt. Ltd.) and are 
uncorrected. Chemical tests were performed to confirm the presence 
of functional groups and required elements. IR spectra of the 
synthesized compounds were recorded on FT-IR Affinity-1 
(Shimadzu) IR Spectrometer. Mass spectra were recorded on LC-MS 
(Shimadzu). NMR spectra were recorded on Bruker 400 MHz 
spectrometer using DMSO-d6 as a solvent.  
Synthesis 
Step-I: Synthesis of phenyl salicylate 
Phenyl salicylate was prepared by esterification of salicylic acid with 
phenol in presence of phosphorous oxychloride [10]. Equimolar 
quantities of salicylic acid and phenol were refluxed for 6 h in 
presence of small quantity of phosphorous oxychloride to give 
phenyl salicylate. The product was washed with water and dried. 
The reaction was monitored by thin layer chromatography (TLC) 
with hexane:ethyl acetate (3:1) as a solvent system and was purified 
by column chromatography.  
Step-II: Synthesis of N-phenyl salicylamide 
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Step-III: Synthesis of derivatives 
The acid catalyzed condensation was carried out to synthesize the 
final derivatives of 1, 3-benzoxazin-4-one [12]. (0.85 g (0.004 M) of 
N-phenyl salicylamide and equimolar quantity of aldehydes were 
added to 20 ml of chloroform and 10 ml of glacial acetic acid. The 
reaction mixture was refluxed for 2 h at 50 ºC with continuous 
passage of HCl gas through the reaction vessel. The reaction was 
monitored by TLC using different solvent systems as specified in 
table 1. The reaction vessel was cooled and the chloroform was 
evaporated on rotary evaporator. 200 ml of cold water was added to 
the reaction mixture. The precipitate was triturated with 5 % NaOH 
solution and again washed with water. The product was re-
crystallized from ethanol and purified with column chromatography.  
Synthesis of derivatives 
Nine 2, 3-aryl substituted 1, 3-benzoxazin-4-ones derivatives were 
synthesized (Fig.1) (Table 1). All compounds were tested for their 
in-vitro antiproliferative activity against MCF7 cell lines.  
 
Fig. 1: Synthetic scheme of all derivatives
 
Table 1: 1, 3-benzoxazin-4-one derivatives 
Compound 
Code 
R R1 R2 R3 Molecular weight 4 % yield Melting Point (0 RC) f 
1 H H N(CH3 H ) 344.41 84.86 238-240 0.36* 
2 H H OH H 317.34 78.05 254-256 0.67* 
3 OH CH H 3 H 361.39 78.82 241-243 0.82* 
4 OH H H CH 347.36 3 67.74 235-237 0.20
5 
# 
OH H H OCH 331.36 3 82.22 232-234 0.39
6 
# 
H H OCH OCH3 315.17 3 81.73 220-222 0.24* 
7 H H OH OCH 331.36 3 73.25 247-249 0.40* 
8 H H CH H 3 317.34 70.25 276-278 0.80* 
9 OH H H H 347.36 74.87 250-252 0.30** 
 *Hexane: Ethyl acetate (1:1), #
 
Synthesis of 2-[4-(dimethylamino) phenyl]-3-phenyl-2, 3-
dihydro-4H-1, 3-benzoxazin-4-one (1) 
It was synthesized by using 0.60 g (0.004 M) of 4-
dimethyaminobenzaldehyde in the above procedure mentioned 
under the synthesis of derivatives. It yielded 1.18 g (85 %) of 
reddish brown solid product. Mp. 238-240 ºC. FTIR (KBr, cm
Benzene:Chloroform(1:1), **Benzene: Methanol(3:1) 
-1): 
3294 (Aromatic -C-H str.), 3026 (-C-H str.), 1722 (-C=O str.), 1620 (-
C=O str.), 1197 (-C-N str.), 896 (-C-H bending); 1H NMR (400 MHz, 
DMSO-d6): δ 1.50 (s, 3H), 1.39 (s, 2H), 6.93 (t, J=8 Hz, 2H), 7.02 (d, 
J=1.6 Hz, 2H), 7.33-7.66 (m, 9H); 13C NMR (100 MHz, DMSO-d6): δ 
35.41, 127.59, 138.11, 142.82, 144.37, 147.51, 156.13, 168.23. LCMS 
(ESI, m/z) 345.2 (M+H)+. 
Synthesis of 2-(4-hydroxyphenyl)-3-phenyl-2, 3-dihydro-4H-1, 
3-benzoxazin-4-one (2) 
It synthesized by using 0.49 g (0.004 M) of 4-hydroxybenzaldehyde 
in the above procedure mentioned under the synthesis of 
derivatives. It yielded 1.0 g (78 %) of greenish white solid product. 
Mp. 254-256 ºC. FTIR (KBr, cm-1): 3319 (Aromatic –O-H str.), 3022 
(Aromatic -C-H str.), 1593 (-C=O str.), 1161 (-C-N str.), 825 (-C-H 
bending); 1H NMR (400 MHz, DMSO-d6): δ 6.90- 7.22 (m, 6H), 7.52-
7.72 (m, 7H), 9.53 (s, 1H); 13C NMR (100 MHz, DMSO-d6): δ 114.27, 
127.59, 138.11, 142.82, 169.33. LCMS (ESI, m/z) 318.4 (M+H)+
It was synthesized by using 0.55 g (0.004 M) of 2-hydroxy-3-
methylbenzaldehyde in the above procedure mentioned under the 
synthesis of derivatives. It yielded 1.10 g (82 %) of yellowish white 
solid product. Mp. 241-243 ºC. FTIR (KBr, cm
. 
Synthesis of 2-(2-hydroxy-3-methylphenyl)-3-phenyl-2, 3-
dihydro-4H-1, 3-benzoxazin-4-one (3) 
-1): 3377 (Aromatic –O-
H str.), 2999 (Aromatic -C-H str.), 2929 (-C-H str.), 1610 (-C=O str.), 
1174 (-C-N str.), 866 (-C-H bending); 1H NMR (400 MHz, DMSO-d6): 
δ 1.88 (s, 3H), 4.23 (s, 1H), 6.93 (d, J= 8 Hz, 1H), 7.32 (d, J= 8.6 Hz, 
1H), 7.33-7.66 (m, 9H), 7.65 (s, 1H); 13C NMR (100 MHz, DMSO-d6): δ 
47.41, 127.55, 135.11, 142.82, 142.99, 143.37, 147.51, 156.13, 
171.03. LCMS (ESI, m/z) 331.2 (M)+. 
Synthesis of 2-(2-hydroxy-5-methylphenyl)-3-phenyl-2, 3-
dihydro-4H-1, 3-benzoxazin-4-one (4) 
It was synthesized by using 0.55 g (0.004 M) of 2-hydroxy-5-
methylbenzaldehyde in the above procedure mentioned under the 
synthesis of derivatives. It yielded 0.98 g (73 %) of yellowish white 
solid product. Mp. 235-237 ºC. FTIR (KBr, cm-1): 3377 (Aromatic –O-
H str.), 2999 (Aromatic -C-H str.), 2929 (-C-H str.), 1610 (-C=O str.), 
1174 (-C-N str.), 866 (-C-H bending); 1H NMR (400 MHz, DMSO-d6): 
δ 1.88 (s, 3H), 4.23 (s, 1H), 6.93 (d, J= 8 Hz, 1H), 7.32 (d, J=8.6 Hz, 
1H), 7.33-7.66 (m, 9H), 7.65 (s, 1H); 13C NMR (100 MHz, DMSO-d6): 
δ 47.41, 127.55, 135.11, 142.82, 142.99, 143.37, 147.51, 156.13, 
171.03. LCMS (ESI, m/z) 331.2 (M)+. 
Synthesis of 2-(2-hydroxy-5-methoxyphenyl)-3-phenyl-2, 3-
dihydro-4H-1, 3-benzoxazin-4-one (5) 
It was synthesized by using 0.61 g (0.004 M) of 2-hydroxy-5-
methoxybenzaldehyde in the above procedure mentioned under the 
synthesis of derivatives. It yielded 1.05 g (75 %) of white solid 
product. Mp. 232-234 ºC. FTIR (KBr, cm-1): 3315 (Aromatic –O-H 
str.), 3026 (Aromatic -C-H str.), 2966 (-C-H str.), 2852 (-O-C str.), 
1618 (-C=O str.), 1238 (-C-O-C str.), 1155 (-C-N str.), 896 (-C-H 
bending); 1H NMR (400 MHz, DMSO-d6): δ 3.73 (s, 3H), 4.00 (s, 1H), 
7.09 (d, J=8 Hz, 1H), 7.23 (d, J=8.6 Hz, 1H), 7.55-7.66 (m, 9H), 7.99 (s, 
1H); 13C NMR (100 MHz, DMSO-d6): δ 40.31, 127.55, 135.11, 140.82, 
142.99, 144.37, 168.23. LCMS (ESI, m/z) 347.76 (M)+
It was synthesized by using 0.67 g (0.004 M) of 3, 4-
dimethoxybenzaldehyde in the above procedure mentioned under 
the synthesis of derivatives. It yielded 1.15 g (79 %) of yellowish 
solid product. Mp. 220-222 ºC. FTIR (KBr, cm
. 
Synthesis of 2-(3, 4-dimethoxyphenyl)-3-phenyl-2, 3-dihydro-
4H-1, 3-benzoxazin-4-one (6) 
-1): 3296 (Aromatic -C-
Kandale et al. 
Int J Pharm Pharm Sci, Vol 6, Issue 7, 68-71 
70 
H str.), 3026 (Aromatic -C-H str.), 2922 (-C-H str.), 2852 (-O-C str.), 
1620 (-C=O str.), 1236 (-C-O-C str.), 1153 (-C-N str.), 896 (-C-H 
bending); 1H NMR (400 MHz, DMSO-d6): δ 3.60 (s, 3H), 4.00 (s, 3H), 
6.90- 7.09 (m, 5H), 7.23 (m, 4H), 7.55 (d, J= 8 Hz, 1H), 7.62 (d, J= 8 
Hz, 1H), 7.82 (s, 1H); 13C NMR (100 MHz, DMSO-d6): δ 40.21, 135.11, 
143.00, 144.37, 157.68, 169.22. LCMS (ESI, m/z) 361.06 (M)+. 
Synthesis of 2-(4-hydroxy-3-methoxyphenyl)-3-phenyl-2, 3-
dihydro-4H-1, 3-benzoxazin-4-one (7) 
It was synthesized by using 0.61 g (0.004 M) of 4-hydroxy-3-
methoxybenzaldehyde in the above procedure mentioned under the 
synthesis of derivatives. It yielded 0.95 g (68 %) of greenish white 
solid product. Mp. 247-249 ºC. FTIR (KBr, cm-1): 3315 (Aromatic –O-
H str.), 3026 (Aromatic -C-H str.), 2966 (-C-H str.), 2852 (-O-C str.), 
1618 (-C=O str.), 1238 (-C-O-C str.), 1155 (-C-N str.), 896 (-C-H 
bending); 1H NMR (400 MHz, DMSO-d6): δ 3.73 (s, 3H), 4.00 (s, 1H), 
7.09 (d, J=8 Hz, 1H), 7.23 (d, J=8.6 Hz, 1H), 7.55-7.66 (m, 9H), 7.99 (s, 
1H); 13C NMR (100 MHz, DMSO-d6): δ 40.31, 127.55, 135.11, 140.82, 
142.99, 144.37, 168.23. LCMS (ESI, m/z) 347.76 (M)+. 
Synthesis of 2-(4-methylphenyl)-3-phenyl-2, 3-dihydro-4H-1, 3-
benzoxazin-4-one (8) 
It was synthesized by using 0.48 g (0.004 M) of 4-
methylbenzaldehyde in the above procedure mentioned under the 
synthesis of derivatives. It yielded 1.04 g (82 %) of brown colored 
solid product. Mp. 276-278 ºC. FTIR (KBr, cm-1): 3250 (Aromatic –C-
H str.), 3022 (Aromatic C-H str.), 1693 (-C=O str.), 1111 (-C-N str.), 
876 (-C-H bending); 1H NMR (400 MHz, DMSO-d6): δ 1.34 (s, 3H), 
7.10- 7.22 (m, 6H), 7.55-7.62 (m, 7H); 13C NMR (100 MHz, DMSO-d6): 
δ 114.27, 126.77, 129.10, 127.59, 138.11, 142.82, 169.33. LCMS (ESI, 
m/z) 315.37 (M)+. 
Synthesis of 2-(2-hydroxyphenyl)-3-phenyl-2, 3-dihydro-4H-1, 
3-benzoxazin-4-one (9) 
It was synthesized by using 0.49 g (0.004 M) of 2-
hydroxybenzaldehyde in the above procedure mentioned under the 
synthesis of derivatives. It yielded 0.90 g (70 %) of greenish white 
solid product. Mp. 250-252 ºC. FTIR (KBr, cm-1): 3399 (Aromatic –O-
H str.), 3024 (Aromatic C-H str.), 1593 (-C=O str.), 1122 (-C-N str.), 
885 (-C-H bending); 1H NMR (400 MHz, DMSO-d6): δ 5.22 (s, 1H), 
6.90- 7.22 (m, 6H), 7.63-7.73 (m, 7H); 13C NMR (100 MHz, DMSO-d6): 
δ 124.27, 127.59, 136.11, 142.82, 171.31. LCMS (ESI, m/z) 317.17 
(M)+. 
In-vitro Antiproliferative activity 
Maintenance of cell lines 
MCF-7 cells were procured from national centre for cell sciences 
(NCCS) Pune, India and were grown in 75 cm2 tissue culture flasks 
containing Eagle’s minimum essential medium (EMEM) 
supplemented with 10 % fetal bovine serum (FBS), 1 % L- glutamine 
and 50 μg/ml Gentamycin sulphate at 37 ºC in a CO2 incubator in an 
atmosphere of humidified 5 % CO2 and 95 % air. The cells were 
maintained by routine sub culturing in 75 cm2 tissue culture flasks. 
Preservation of tumor cells from the first and second passage of 
transplantation were stored in liquid nitrogen in cryovials 
containing Iscove’s Modified Dulbecco’s Media (IMDM) 
supplemented with 10 % FBS and 10 % dimethyl sulphoxide 
(DMSO) as a preservative at concentration of 106 cells/ml. This 
constituted the tumor bank. After every 10 passages, tumor cell line 
was discarded and new passage was started using the original tumor 
cells from the tumor bank. 
MTT assay method
The assay was performed as per the reported protocols [13, 14]. 
Exponentially growing MCF-7 cells were harvested from 75 cm
 
2 
tissue culture flask and a stock cell suspension (1x105 cell/ml) was 
prepared. A 96-well flat bottom tissue culture plate was seeded with 
2 x 103 cells in 0.1 ml of EMEM medium supplemented with 10% 
FBS and allowed to attach for 24 h. Test compounds were prepared 
just prior to the experiment in DMSO to get 10000 μg/ml. After 24 h 
of incubation, cells were treated with test compounds to get a final 
dose of 12.5, 25, 50 and 100 μg in respective wells and incubated for 
48 h. The cells in the control group received only the medium 
containing 0.2 % DMSO. Each treatment was performed in 
duplication. After the treatment, drug containing media was 
removed and washed with 200 μl of FBS. To each well of the 96 well 
plate, 100 μl of MTT reagent (Stock: 1 mg/ml in serum free medium) 
was added and incubated for 4 h at 37 ºC. After 4 h of incubation, the 
plate was inverted on tissue paper to remove the MTT reagent. To 
solubilize formazan crystals in the wells, 100 μl of 100 % DMSO was 
added to each well. The optical density was measured by micro-titer 
plate reader at 590 nm. Percentage cytotoxicity of each compound 
was calculated by using the formula (Control - Blank) - (Test - Blank) 
X 100 / (Control-Blank). 
RESULTS AND DISCUSSION 
In vitro antiproliferative activity (MTT assay) 
The percentage inhibition of test compounds was measured after 24 
h and 48h. After 24 h incubation, 4 out of 9 compounds (2, 7, 8 and 
9) showed more than 75 % inhibition at 100 µg (Fig. 2). After 
incubation for 48 h, 8 out of 9 compounds showed more than 75 % 
inhibition at 100 µg and 4 compounds showed more than 90 % 
inhibition when tested with the same maximum dose (Fig. 3). All 
compounds inhibited MCF-7 cells in a dose dependent manner after 
24 as well as 48 h (Fig. 2 and 3). Compound 2 showed the maximum 
activity with an IC50 of 0.89 µg followed by compound 4 and 3 with 
an IC50 of 1.02 and 1.19 µg respectively. Compound 2 also showed 
77.26 % inhibition of cell lines at 12.5 µg and 98.18 % inhibition at 
highest dose (100 µg) after 48 h incubation. Compound 9 also 
showed 98.38 % inhibition of cell lines at 100 µg but its IC50 was 
found to be more compared to compound 2, 3 and 4. All other 
compounds showed less activity among which, compound 6 was 
least active with an IC50
 
Fig. 2: Inhibition of MCF-7 cells after 24 h inhibition 
 
 of 51.55 µg. 
 
Fig. 3: Inhibition of MCF-7 cells after 48 h inhibition 
 
CONCLUSION 
All synthesized compounds showed activity against MCF-7 cell lines. 
Few compounds (2,3 and 4) showed promising activity by inhibiting 
the MCF-7 cell lines by more than 90 %. From this study, we could 
conclude that benzoxazinone derivatives with substitutions at 2 and 
3 positions can be a good class of compounds against MCF-7 cell 
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lines. This class of compounds may further be explored by synthesizing 
more compounds and testing them against MCF-7 cell lines.  
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